Why Is Praxis Precision Stock Soaring Tuesday?

Praxis Precision Medicines (NASDAQ: PRAX) shares surged 7.15% on Tuesday following FDA acceptance of its New Drug Application for ulixacaltamide, a treatment for essential tremor, with an FDA decision target date of January 29, 2027. The company also reported positive Phase 3 trial results and significant seizure reduction data from its elsunersen program. The stock is trading near its 52-week high with strong technical momentum and a Buy rating from analysts with a $588.60 average price target.

04/14/2026, 2:02 PM • Benzinga

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Praxis Precision Medicines announced positive Phase 1/2 trial results for elsunersen (PRAX-222), an antisense oligonucleotide treatment for SCN2A developmental and epileptic encephalopathy. The drug demonstrated a 77% placebo-adjusted seizure reduction, with 71% of treated patients achieving >50% seizure reduction. All elsunersen-treated patients showed improvements in sleep, motor function, and attention, with no serious adverse events reported.

04/06/2026, 8:00 AM • GlobeNewswire

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter

Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (PRAX) in Q4 2025 for $9.31 million, but the position still increased by $227 million in value due to stock appreciation. PRAX remains Cormorant's largest holding at $280 million. The biotech stock has surged 700% over the past year and is advancing multiple late-stage therapies for neurological disorders with strong cash reserves of $926 million.

03/16/2026, 6:23 PM • The Motley Fool

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline

Deerfield Management Company increased its stake in Praxis Precision Medicines by 62,500 shares, bringing its total position to $266.25 million. PRAX stock has surged 685% over the past year, significantly outperforming the S&P 500. The biotech company recently submitted FDA applications for two drug candidates and has four leading programs that could represent over $20 billion in potential revenue if successfully commercialized. With $926 million in cash and a recent $621 million offering, Praxis is well-positioned financially through 2028.

03/13/2026, 10:14 AM • The Motley Fool

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings

Praxis Precision Medicines (PRAX) has surged 685% over the past year, attracting an $80.5 million investment from Driehaus Capital Management. The clinical-stage biotech company recently submitted two FDA applications for therapies targeting essential tremor and rare developmental epilepsies. With $926 million in cash and potential revenue exceeding $20 billion if approved, the company is positioned for significant growth, though regulatory approval remains a key risk.

03/13/2026, 9:23 AM • The Motley Fool

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

Perceptive Advisors increased its stake in Praxis Precision Medicines by 431,432 shares (worth ~$80.34 million) in Q4 2025, bringing its total position to $588.30 million and making it the fund's largest holding at 10.8% of AUM. The biotech company's stock has surged 320% over the past year as it advances toward commercialization with two FDA NDAs submitted and a strong cash position of $1.547 billion.

02/22/2026, 2:16 PM • The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares

Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.

02/13/2026, 7:34 AM • The Motley Fool

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Praxis Precision Medicines announced strategic leadership changes to support its transition into late-stage development and commercial execution. The company appointed Jeffrey B. Kindler (former Pfizer CEO) and Stuart Arbuckle (former Vertex COO) to its board of directors, and promoted Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. These moves align with the company's focus on commercial launch planning, late-stage development, and strategic value optimization for its CNS disorder therapies.

01/08/2026, 4:45 PM • GlobeNewswire

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Praxis Precision Medicines priced an underwritten public offering of 2.212 million shares at $260 per share, generating approximately $575 million in gross proceeds. The offering is expected to close on January 8, 2026, with underwriters granted a 30-day option to purchase an additional 331,800 shares. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder therapies.

01/06/2026, 11:15 PM • GlobeNewswire

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, announced a proposed public offering of common stock and pre-funded warrants. The offering is being managed by Piper Sandler, TD Cowen, Guggenheim Securities, and Truist Securities as joint book-running managers, with completion subject to market conditions.

01/06/2026, 4:03 PM • Benzinga

Why Praxis Precision Medicines Stock Popped Today

Praxis Precision Medicines stock surged 13.25% after receiving FDA Breakthrough Therapy Designation for ulixacaltamide, an experimental treatment for essential tremor. The designation, based on positive phase 3 study results, will accelerate the drug's development and regulatory review, with a New Drug Application planned for early 2026. Essential tremor affects approximately 7 million people in the U.S. with limited effective treatment options.

12/29/2025, 7:19 PM • The Motley Fool

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Praxis Precision Medicines received FDA Breakthrough Therapy Designation for ulixacaltamide, a T-type calcium channel inhibitor for essential tremor treatment, based on positive Phase 3 Essential3 program results. The company plans to submit a New Drug Application (NDA) in early 2026 following a successful pre-NDA meeting with the FDA.

12/29/2025, 8:00 AM • GlobeNewswire

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?

Praxis Precision Medicines reported positive results from its EMBOLD study for SCN2A and SCN8A developmental and epileptic encephalopathies, leading to a significant stock price increase and potential FDA review.

12/05/2025, 5:03 AM • Benzinga

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Praxis Precision Medicines plans to raise approximately $525 million through a public offering of 3,025,480 common stock shares and pre-funded warrants at $157.00 per share, with underwriters including TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities.

10/16/2025, 11:45 PM • GlobeNewswire

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

Law firm investigating Praxis Precision Medicines after reporting adverse events in mid-stage drug study, which caused stock price to drop 5.55%.

09/15/2025, 5:42 PM • GlobeNewswire